Search

Your search keyword '"Golmard L."' showing total 152 results

Search Constraints

Start Over You searched for: Author "Golmard L." Remove constraint Author: "Golmard L."
152 results on '"Golmard L."'

Search Results

1. Retinoblastoma: From genes to patient care

5. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

8. GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE A RATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS

10. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

11. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

12. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

13. Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial

14. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

16. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

17. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

18. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

19. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

20. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

21. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

22. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

23. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

24. BRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial

25. Location of mutation in BRCA2 gene and survival in patients with ovarian cancer

26. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

27. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

28. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

29. Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers

30. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

32. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations

35. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

36. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

37. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism

38. Incomplete segregation of MYH11 variants with thoracic aortic aneurysms and dissections and patent ductus arteriosus

39. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

40. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

43. Genotype-phenotype correlation in 104 patients with vascular Ehlers-Danlos syndrome: Evidence for a mild form of the disease

46. A new cryptic CFTR exon in mild CF

48. Breast and ovarian cancer predisposition due to de novo BRCA1and BRCA2mutations

49. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial

50. Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.

Catalog

Books, media, physical & digital resources